Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
SNDX Stock Chart & Stats
$20.72
$0.12(0.87%)
At close: 4:00 PM EST
$20.72
$0.12(0.87%)
Day’s Range― - ―
52-Week Range$8.58 - $21.22
Previous CloseN/A
Volume201.89K
Average Volume (3M)2.50M
Market Cap
$1.80B
Enterprise Value$1.24B
Total Cash (Recent Filing)$454.17M
Total Debt (Recent Filing)$345.43M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Mar 09, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding86,914,840
10 Day Avg. Volume1,894,185
30 Day Avg. Volume2,498,597
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.93
Price to Sales (P/S)47.80
P/FCF Ratio-4.12
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue11.13
Enterprise Value/Gross Profit12.06
Enterprise Value/Ebitda-4.21
Forecast
1Y Price Target
$38.50Price Target Upside85.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.09
Revenue Forecast (FY)$167.57M
Bulls Say, Bears Say
Bulls Say
Commercial SuccessRevuforj continues to outperform early-launch benchmarks, is moving earlier into lines of therapy, and is demonstrating the type of real-world impact that typically cements prescriber habit formation.
Market ExpansionRevuforj is now the first and only menin inhibitor approved in both NPM1-mutant and KMT2A-rearranged AML, reinforcing its commercial first-mover advantage.
Regulatory ApprovalRevuforj received FDA approval for the treatment of relapsed or refractory NPM1-mutated AML, expanding its reach into the largest molecularly defined AML subgroup.
Bears Say
Dosing RegimenExperts noted that work still needs to be done to find the optimal maintenance dosing regimen.
Investor ConcernsShares traded down approximately 8% due to investor concerns over the expanded boxed warning, though it is not viewed as a significant commercial impediment.
Regulatory ChallengesFDA approved the sNDA for Revuforj for R/R NPM1m AML—but notably added QTc prolongation to the Black Box.
Syndax Pharmaceuticals News
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $8.58 and its highest was $21.22 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Syndax Pharmaceuticals Inc’s market cap is $1.80B.
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Mar 09, 2026 which is in 81 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Nov 03, 2025. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.724 by $0.024.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -0.59.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 86,914,840 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.724. Following the earnings report the stock price went up 11.555%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SNDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syndax Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.50 (85.81% Upside)
$38.50 (85.81% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 342.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.89%
12-Months-Change
Fundamentals
Return on Equity
-129.32%
Trailing 12-Months
Asset Growth
29.59%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biotechnology sector, with a commitment to discovering, developing, and delivering novel therapies that address unmet needs in oncology. Its core products include a pipeline of drug candidates designed to enhance the effectiveness of existing cancer treatments and improve patient outcomes.
SNDX Company Deck
SNDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Syndax showed strong revenue growth and successful product launches, with Revuforj expanding its market potential significantly through an FDA approval. However, temporary treatment pauses and higher gross to net adjustments posed challenges in realizing full revenue potential.View all SNDX earnings summariesSNDX Stock 12 Month Forecast
Average Price Target
$38.50
▲(85.81% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
13.77% Mutual Funds
47.94% Other Institutional Investors
23.23% Public Companies and Individual Investors